Halozyme Therapeutics (HALO)

Add to Watchlists
Create an Alert
7.57 +0.02  +0.26% NASDAQ Apr 17, 8:00PM BATS Real time Currency in USD
View Full Chart
HALO Price Chart
View All Events

HALO Events

Date Type Description
Feb 27 Misc Halozyme Therapeutics, Inc. Q4 2013 Earning Conference Call
Feb 27 Earnings Halozyme Therapeutics, Inc. Q4 2013 Earning Result. Estimate: -0.17.
Nov 08 Misc Halozyme to Host Third Quarter 2013 Financial Results Conference Call
Nov 07 Earnings Halozyme to Host Third Quarter 2013 Financial Results. Estimate: -0.14.
Aug 07 Misc Halozyme to Host Second Quarter 2013 Financial Results Conference Call
Aug 07 Earnings Second Quarter 2013 Financial Results. Estimate: -0.14.
May 16 Misc AGM Event for Halozyme Therapeutics Inc.
May 08 Misc Halozyme to Host First Quarter 2013 Financial Results Conference Call
May 08 Earnings Halozyme to Host First Quarter 2013 Financial Results Conference Call. Estimate: -0.15.
View All Performance Charts

HALO Total Returns Comparison

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Halozyme Therapeutics is up 31.88% over the last year vs S&P 500 Total Return up 23.54%, Roche Holding up 22.78%, and Alkermes up 48.45%.

Get Quote for

PDF Report for HALO

Download Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.

Download HALO Pro Report PDF
Advertisement

Portfolio Strategies Featuring HALO

Did Halozyme Therapeutics make it into our Portfolio Strategies?
Start your YCharts membership now to find out.

HALO Profile

  • Sector: Healthcare
  • Industry: Biotechnology
  • Headquarters Country: United States
  • Headquarters State/Province: California
  • Incorporation Country: United States
  • Incorporation State/Province: Delaware
  • Est. Current Fiscal Quarter End: June 30, 2014
  • Est. Current Fiscal Year End: December 31, 2014
  • Last Fiscal Quarter End: N/A
  • Last Fiscal Year End: N/A
  • NAICS: Biological Product (except Diagnostic) Manufacturing
  • NAICS Code: 325414
  • NAICS Industry: Pharmaceutical and Medicine Manufacturing
  • NAICS Industry Code: 3254
  • NAICS Sector: Manufacturing
  • NAICS Sector Code: 32

Halozyme Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes that either transiently modify tissue under the skin to facilitate injection of other therapies or correct diseased tissue structures for clinical benefit. The company's products targeting the area outside the cell known as the extracellular matrix, or Matrix. The company has partnership with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc., or Roche, to apply Enhanze Technology to Roche's biological therapeutic compounds for up to eight targets; and with Baxter Healthcare Corporation to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID. Halozyme Therapeutics, Inc. was founded by Gregory Ian Frost in 1998 and is based in San Diego, California.

Recent Quotes

Symbol Price Chg Chg % Market Cap
HALO 7.57 +0.02 +0.26% 938.71M
Create Watchlist from Quotes
Advertisement

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

required
required
required
required
required
Get Started Now
document.write('');

{{root.upsell.info.feature_headline}}.
Upgrade to {{root.upsell.info.tier_name}}. Start Your YCharts Membership. Start your {{root.upsell.info.tier_name}} Membership

{{root.upsell.info.feature_description}}

{{root.upsell.info.is_upgrade ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{root.upsell.info.tier_name}} Member? Sign in here.